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Receptors recognizing the Fc part of immunoglobulin G (FcγRs) are key determinants in 27 
antibody-mediated immune responses. Members of the Herpesviridae interfere with this 28 
immune regulatory network by expressing viral FcγRs (vFcγRs). Human cytomegalovirus 29 
(HCMV) encodes four distinct vFcγRs that differ with respect to their IgG-subtype specificity 30 
and their impact on antibody-mediated immune function in vitro. The impact of vFcγRs on 31 
HCMV pathogenesis and immunomodulation in vivo is not known. The evolutionary closest 32 
animal model of HCMV is rhesus CMV (RhCMV) infection of rhesus macaques. To enable 33 
the characterization of vFcγR function in this model, we studied IgG binding by RhCMV. We 34 
show that lysates of RhCMV-infected cells contain an IgG-binding protein of 30kDa encoded 35 
by the gene Rh05 that is a predicted type I glycoprotein belonging to the RL11 gene family. 36 
Upon deletion of Rh05, IgG-Fc binding by RhCMV strain 68-1 is lost whereas ectopic 37 
expression of Rh05 results in IgG binding to transfected cells consistent with Rh05 being a 38 
vFcγR. Using a set of reporter cell lines stably expressing human and rhesus FcγRs we further 39 
demonstrate that Rh05 antagonizes host FcγR activation. Compared to Rh05-intact RhCMV, 40 
RhCMVΔRh05 showed an increased activation of host FcγR upon exposure of infected cells 41 
to IgG from RhCMV-seropositive animals suggesting that Rh05 protects infected cells from 42 
opsonization and IgG-dependent activation of host FcγRs. However, antagonizing host FcγR 43 
activation by Rh05 was not required for the establishment and maintenance of infection of 44 
RhCMV, even in a seropositive host, as shown by the induction of T cell responses to 45 
heterologous antigens expressed by RhCMV lacking the gene region encoding Rh05. In 46 
contrast to viral evasion of NK cells or T cell recognition, the evasion of antibody-mediated 47 
effects does not seem to be absolutely required for infection or re-infection. The identification 48 
of the first vFcγR that efficiently antagonizes host FcγR activation in the RhCMV genome 49 
will thus permit more detailed studies of this immunomodulatory mechanism in promoting 50 
viral dissemination in the presence of natural or vaccine-induced humoral immunity.  51 







Importance  52 
Rhesus cytomegalovirus (RhCMV) offers a unique model for studying human 53 
cytomegalovirus (HCMV) pathogenesis and vaccine development. RhCMV infection of non-54 
human primates greatly broadened the understanding of mechanisms by which CMVs evade 55 
or re-program T cell and NK cell responses in vivo. However, the role of humoral immunity 56 
and viral modulation of anti-CMV antibodies has not been studied in this model. There is 57 
evidence from in vitro studies that HCMVs can evade humoral immunity. By gene mapping 58 
and with the help of a novel cell-based reporter assay system we characterized the first 59 
RhCMV encoded IgG-Fcɣ binding glycoprotein as a potent antagonist of rhesus FcγR 60 
activation. We further demonstrate that, unlike evasion of T cell immunity, this viral Fcγ 61 
receptor is not required to overcome anti-CMV immunity to establish secondary infections. 62 
These findings enable more detailed studies of the in vivo consequences of CMV evasion 63 
from IgG responses in non-human primate models. 64 
 65 
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As prototypical members of the β-subgroup of the herpesvirus family, cytomegaloviruses 68 
(CMVs) establish lifelong infection characterized by viral latency and reactivation. Human 69 
and animal CMVs share sophisticated mechanisms to evade a multitude of antiviral host 70 
immune responses including both innate and adaptive arms of the immune system (1, 2). With 71 
respect to cell-mediated immunity, it has been shown that human cytomegalovirus (HCMV) 72 
can efficiently evade direct recognition of infected target cells by natural killer (NK) cells as 73 
well as T lymphocytes using a large repertoire of viral gene products that interfere with 74 
antigen presentation, surface receptor transport or innate receptor signaling (3, 4). 75 
Complementing viral evasion of cell-mediated immune responses are strategies for evasion of 76 
humoral immunity such as counteracting IgG-mediated antiviral immunity. Ribosomal 77 
profiling identified more than 750 translational products that include many potentially 78 
antigenic proteins during the sequential immediate-early (IE), early (E) and late (L) phases of 79 
gene expression (5). Despite exposure of these potential viral antigens to the host’s immune 80 
system, human and animal CMVs maintain lifelong chronic infections with occasional 81 
reactivation. Moreover, CMVs are able to reinfect CMV-immune hosts despite the presence 82 
of CMV-specific humoral and cellular immune responses (6, 7). Potentially due to viral 83 
immune evasion capabilities, anti-HCMV IgG preparations such as intravenous hyperimmune 84 
immunoglobulin (IVIG) or monoclonal antibodies (mAbs) displayed only limited, if any, 85 
efficacy in various clinical settings (8-13). In non-human primate models, prevention of fetal 86 
transmission only occurred when IVIG was concentrated from plasma of donors that were 87 
pre-selected for high neutralization activity whereas IVIG from non-selected plasma was only 88 
partially protective suggesting that RhCMV is able to escape antibody control (14).  89 
Specific viral mechanisms that counteract antibody effector functions might be responsible for 90 
limiting the ability of antibodies to control viral infection and dissemination. HCMV evasion 91 
from IgG-Fc mediated effector functions can be attributed to a set of IgG-Fc binding 92 







glycoproteins (vFcγRs) encoded by the HCMV genes UL118/119 (gp68) and RL11 (gp34) 93 
(15). These vFcγRs were shown to efficiently antagonize host IgG-Fc receptor (FcγR) 94 
activation in a cell-based in vitro reporter assay performed on IVIG-opsonized infected cells 95 
(16). In addition, RL12 and RL13 have been shown to have vFcγR activity (14). While 96 
HCMV is the only known human β-herpesvirus to encode such glycoproteins, it is not the 97 
only herpesvirus for which vFcγRs have been described. Mouse cytomegalovirus (MCMV) 98 
encodes the Ig-like glycoprotein fcr-1/m138 (17). Deletion of m138 from the MCMV genome 99 
results in drastic attenuation of MCMV in vivo (18). However, since m138 has both Fcγ-100 
related and -unrelated immunoevasive functions (19-21) the role of Fcγ-modulation for viral 101 
pathogenesis has yet to be established. HSV-1 and VZV glycoproteins E and I (gE/gI) form 102 
an IgG-Fc binding heterodimer (22, 23). By clearing antigen/antibody complexes from the 103 
infected cell surface (24) the HSV-1 gE/gI complex promotes immune evasion in vivo (25). 104 
Interestingly, the VZV gE protein is the major component of the recently developed highly 105 
efficient subunit VZV vaccine (26).  106 
Immune responses most prominently governed by host FcγRs include antibody dependent 107 
cell-mediated cytotoxicity (ADCC), antibody dependent cell-mediated phagocytosis (ADCP) 108 
and the induction of a pro-inflammatory cytokine profile by various immune cells including 109 
NK cells, macrophages, dendritic cells, B cells and neutrophils expressing FcγRs (27). FcγRs 110 
are further classified by their affinity to IgG-Fc and are highly conserved between humans 111 
and non-human primates showing strong cross-reactivity (28, 29). There are four known 112 
activating receptors comprising the high affinity receptor CD64/FcγRI, the medium affinity 113 
receptors CD32A/FcγRIIA and CD32C/FcγRIIC, and the low affinity receptor 114 
CD16A/FcγRIIIA. CD32B/FcγRIIB is the only known inhibitory receptor with a medium 115 
affinity to IgG-Fc and a single cytosolic ITIM motif (27). Although their affinity to IgG-Fc is 116 
also dependent on the IgG subclass, all FcγRs show their highest affinity towards IgG1 while 117 
optimal binding in general can only be observed to immune complexed IgG with an intact 118 







glycan profile (30). In recent years FcγR-mediated immune responses have proven to be an 119 
essential factor in the antiviral effect of non-neutralizing but also neutralizing IgG specific for 120 
important pathogenic viruses like Influenza A (31, 32) and HIV (33, 34).  121 
CMVs are highly species specific, which prevents studying HCMV directly in an animal 122 
model. While the closest relative of HCMV is chimpanzee CMV (CCMV), experimentation 123 
in these animals is no longer possible. In contrast, infection of rhesus macaques (RM) 124 
(Macaca mulatta) with rhesus cytomegalovirus (RhCMV) is a tractable model and the 125 
genomes of non-human primate (NHP) CMVs encode homologs of most of the HCMV gene 126 
families (35, 36). Therefore, RhCMV infection has emerged as a state of the art model 127 
allowing the study of primate CMV disease infection, immune responses and pathology in 128 
vivo (37), including important aspects of congenital infection (14, 38). While in this model 129 
RhCMV genes linked to evasion from CD8+ T lymphocyte and NK cell responses have been 130 
extensively investigated (6, 39), little is known about the ability of RhCMV to evade antibody 131 
mediated immunity.  132 
Here we demonstrate that the RhCMV RL11 gene family member Rh05 encodes an IgG-Fc 133 
binding glycoprotein. Similar to HCMV vFcγRs, this type 1 transmembrane protein is 134 
transported to the cell surface where it efficiently antagonizes FcγR activation triggered by 135 
immune IgG. In addition, Rh05 was able to antagonize human FcγRIIIa/CD16a activation by 136 
cells opsonized with a rhesusized monoclonal IgG antibody. Interestingly, Rh05 was not 137 
required for RhCMV super-infection, suggesting that evasion of pre-existing antibodies is not 138 
essential for the establishment of secondary infections. These results thus represent the first 139 
identification of a vFcγR in RhCMV and highlight the close evolutionary relationship of 140 
human and rhesus IgG and FcγRs consistent with the RM/RhCMV model being particularly 141 
relevant when studying viral evasion of IgG effector functions in vivo.  142 
 143 
Materials and Methods 144 








Cells. All cells were cultured in a 5% CO2 atmosphere at 37°C. Telomerized rhesus 146 
fibroblasts (TRF), HEK293T cells and Hela cells were maintained in Dulbecco’s modified 147 
Eagle’s medium (DMEM, Gibco) supplemented with 10% (vol/vol) fetal calf serum (FCS, 148 
Biochrom) and antibiotics (1x Pen/Strep, Gibco). TRF were generated from rhesus fibroblasts 149 
(RF) obtained from animals housed at Oregon National Primate Research Center (ONPRC) 150 
and life-extended as described previously (40). BW5147 mouse thymoma cells (BW, obtained 151 




 cells/ml in Roswell Park Memorial 152 
Institute medium (RPMI GlutaMAX, Gibco) supplemented with 10% (vol/vol) FCS, 153 
antibiotics, sodium pyruvate (1x, Gibco) and β-mercaptoethanol (0.1 mM, Gibco). 154 
 155 
Generation of purified Fab and Fc fragments from whole serum. IgG was isolated from 156 
pre-existing serum samples of healthy, RhCMV-naïve RM at the Oregon National Primate 157 
Research Center (ONPRC). Fab and Fc fragments were generated using the Pierce™ Fab 158 
Preparation Kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s 159 
instructions. Protein concentrations of the purified samples were determined using a 160 
NanoDrop® ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA) and equal amounts of 161 
protein for each sample were separated on an SDS polyacrylamide gel. To visualize the 162 
purified fragments, the gel was fixed with methanol and silver stained using the 163 
SilverQuest™ Silver Staining Kit (Thermo Fisher Scientific, Waltham, MA, USA). 164 
 165 
Metabolic labelling of cells. TRFs were grown in 60mm tissue culture dishes (1.5x10
6
 cells 166 
per dish) and removed using a cell-scraper. Cells from two dishes were pooled and transferred 167 
into a 50ml conical tube. The cells were washed twice with PBS and incubated for 1 hour in 168 
starvation mix (DMEM complete without cysteine or methionine). Afterwards, the cells were 169 
pelleted and re-suspended in 1ml starvation mix, transferred into a 1.5ml Safe-Lock 170 







Eppendorf centrifugation tube and 300μCi of 
35
S were added per sample. The cells were 171 
rocked for 30 minutes at 37°C, pelleted and washed once with PBS. Finally the cells were 172 
lysed with NP40 lysis buffer containing protease inhibitors for 45 minutes at 4°C. Cell debris 173 
was removed by centrifugation at 16.100 x g for 20 minutes. The lysates were stored at -80°C. 174 
 175 
Immunoprecipitation of purified Fab, Fc and IgG from metabolically labeled cells. Cell 176 
lysates were pre-cleared by adding protein A/G agarose beads, incubated for 1 hour at 4°C 177 
followed by pelleting the beads by centrifugation. The supernatant was transferred to a new 178 
tube, incubated again with protein A/G agarose beads at 4°C overnight followed by 179 
centrifugation. The pre-cleared lysates were transferred into a new Eppendorf tube and 180 
incubated with 10 μg of either purified Fab, purified Fc or whole IgG with the addition of 181 
protease inhibitors overnight at 4°C. Protein A/G agarose beads were added to the mixture 182 
and the lysates were incubated for 1h while rocking at 4°C. The beads were pelleted, the 183 
supernatant was discarded and the beads were washed four times with NET buffer (50mM 184 
Tris pH 7.5, 5mM EDTA, 150mM NaCl, 0.5% NP-40) before resuspension in EndoH buffer. 185 
The samples were boiled for 10 minutes and split in equal parts with Endoglycosidase H 186 
being added to one part. All samples were incubated at 37°C overnight. 2x Laemmli 187 
Sample Buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue, 188 
0.125M Tris HCl, pH 6.8) was added and the samples were boiled for 5 minutes and frozen at 189 
-80 °C. 190 
 191 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 10% SDS 192 
PAGE gels were generated using standard methods. Half of the immunoprecipitate described 193 
above was loaded onto the gel and electrophoresis was performed for 90 minutes at 100V. 194 
Gels were fixed and dried onto Whatman papers using a Slab Gel Dryer Model SGD5040 195 
(Savant). The dried gel was exposed to autoradiography film at -80°C for at least one week. 196 







The film was developed using an SRX-101A film processor (Konica Minolta, 197 
Marunouchi, Chiyoda, Tokyo, Japan). 198 
 199 
Viruses and construction of recombinant mutants. The primary RhCMV isolate UCD59 200 
was kindly provided by Dr. Peter Barry (UC Davis, CA) and has been isolated from RM at the 201 
CNPRC (41). The primary RhCMV isolates 19269 and 24514, as well as the CyCMV isolate 202 
31908, were isolated from animals at the ONPRC as described (42, 43). 68-1 RhCMV/gag 203 
and 68-1.2 RhCMV/gag were also previously described (44, 45). In both constructs, an 204 
expression cassette for the Simian Immune Deficiency Virus (SIV) Gag gene was inserted 205 
into the Rh211 gene. The ΔRh14-Rh29 deletion mutant was generated on the basis of 68-1 206 
RhCMV/gag by homologous Red-mediated recombination (46) using primers with 50bp 207 
homology flanking the desired deletion. In the ΔRh01-Rh13.1 construct, SIVgag replaced the 208 
gene Rh01 thus using the endogenous Rh01 promoter for SIVgag expression. Downstream of 209 
SIVgag an aminoglycoside 3'-phosphotransferase (KanR) cassette flanked by FRT sides was 210 
inserted which permits selection of recombinant clones and subsequent excision of the 211 
selection marker using a heat shock inducible flippase (FLP) (47). The constructs were 212 
analyzed by restriction digest with XmaI and Sanger sequencing across the introduced 213 
deletion. Recombinant viruses were reconstituted by electroporation of the BAC DNA into 214 
primary RF. Viral cultures were expanded to generate purified viral stocks for experiments. 215 
To generate single ORF deletions in RhCMV we utilized the en passant method that allows 216 
for “scarless” homologous recombination (48). Recombination primers with 100bp overhangs 217 
were designed so that the first 100bp of the sense-primer and the first 50bp of the antisense-218 
primer at the 5’terminal end corresponded to DNA sequences either directly upstream or 219 
downstream of the intended deletion. The 50bp directly upstream of the intended deletion in 220 
the sense-primer were repeated in the antisense-primer to create a homologous sequence in 221 
the intermediate BAC construct. As a template to create the insertion cassette for homologous 222 







recombination, we used a plasmid containing the aminoglycoside 3'-phosphotransferase 223 
(KanR) selectable marker with an upstream I-SceI unique restriction site. The primer binding 224 
sites for the recombination primers were designed to bind the 5’-end of the I-SceI restriction 225 
site and the 3’-end of the KanR selection marker. The KanR cassette was removed by 226 
arabinose induced expression of the I-SceI restriction enzyme in E.coli strain GS1783 and by 227 
simultaneous induction of the Red recombination genes by heat shock, leading to the 228 
homologous recombination of the introduced repeated 50bp sequences and the “scarless” 229 
removal of the targeted ORF. Deletion of the ORF was confirmed by restriction digest with 230 
XmaI and by Sanger sequencing across the deletion. Recombinant viruses were reconstituted 231 
and analyzed as described above. 232 
 233 
Analysis of RhCMVΔRh05 growth kinetics by multi-step growth curve. Primary rhesus 234 
fibroblast were seeded out in 24 well plates (5x10
4
 cells per well) and were infected with 235 
either RhCMV 68-1 or RhCMV 68-1 ΔRh05 at an MOI of 0.01. Supernatants from two wells 236 
per sample and time point were harvested every 3
rd
 day starting at day 3 and the supernatants 237 
were cleared by centrifugation at 16.100 x g for 5 minutes before storing them at -80°C. Viral 238 
titers of each sample were determined by 50% tissue culture infective dose (TCID50) assays 239 
on primary rhesus fibroblasts and the growth curves were graphed using the arithmetic mean 240 
of the two biological repeats per sample. 241 
 242 
Molecular cloning, transient transfection and lentiviral transduction. Rh05 and rhesus-243 
CD4 (ACC# D63347) were synthesized as gBlock fragments flanked by Nhe1 and BamH1 244 
restriction sites (Integrated DNA Technologies, IDT) and cloned into the pIRES_eGFP 245 
expression vector upstream of an internal ribosomal entry site (IRES) and the gene for green 246 
fluorescent protein (GFP). Transient expression of recombinant protein was achieved by 247 
transfection of Hela cells using Superfect transfection reagent (Qiagen). BW-reporter cells 248 







stably expressing chimeric Macaca mulatta Fcγ-receptor-CD3ζ receptors were generated by 249 
lentiviral transduction using HEK293T cells as a packaging cell line. Fcγ-receptor-CD3ζ 250 
chimeric receptors were designed by fusion of the extracellular domain of the respective 251 
rhesus-Fcγ receptors (RhCD16: ACC# XP_014968661; RhCD32a: ACC# XP_014968622; 252 
RhCD32b: ACC# XP_014968682; RhCD64: ACC# NP_001244233) with the mouse CD3 253 
signaling module as described (49). The Rh-Fcγ receptors were synthesized as gBlock 254 
fragments flanked by Nhe1 and BamH1 restriction sites (IDT). gBlocks were then cloned into 255 
the puc2CL6IPwo lentiviral vector using the above mentioned restriction sites. For every 256 
construct one 10 cm dish of packaging cell line at roughly 70% density was transfected with 257 
the target construct and 2 supplementing vectors providing the VSV gagpol and VSV-G-env 258 
proteins (6µg of DNA each) using Polyethylenimine (22.5µg/ml) and Polybrene (4µg/ml, 259 
Merck Millipore) in a total volume of 7 ml (2 ml of 15 min pre-incubated transfection mix in 260 
serum-free DMEM added to 5 ml of fresh full DMEM. After a medium change, virus 261 
supernatant harvested from the packaging cell line two days after transfection was then 262 
incubated with target BW cells overnight (3.5ml supernatant on 1x10
6
 target cells) followed 263 




 BW cells were washed in PBS, equilibrated in staining buffer (PBS, 266 
3% FCS) and sedimented at 1000g and 10°C for 3 minutes. Cells were resuspended in 100µl 267 
of either primary antibody solution followed by conjugate antibody solution or conjugate 268 
antibody solution alone (1/100 in staining buffer). Every incubation step was carried out at 269 
4°C for 1h and followed by 3 washing steps in staining buffer. Dead cells were stained using 270 
DAPI. After the final wash, cells were resuspended in 400µl staining buffer and analyzed on a 271 
FACS Fortessa instrument (BD Bioscience). Human IgG-Fc-TexasRed (Rockland) and anti-272 
human-IgG-FITC (Miltenyi Biotec) were used as conjugates. PE-conjugation was performed 273 
using an ab102918 labelling kit by abcam as suggested by the supplier. 274 








Fcγ-receptor activation assay. The assay was performed as described earlier (49). Briefly, in 276 
a standard assay, target cells were incubated with dilutions of Macaca mulatta sera (RhCMV-277 
infected TRF) or mAbs (transfected Hela) in DMEM supplemented with 10% (vol/vol) FCS 278 
for 30min at 37°C. Cells were washed before co-cultivation with BW-reporter cells (ratio E:T 279 
20:1) for 16h at 37°C in a 5% CO2 atmosphere. Cross-link activation of reporter cells was 280 
performed by direct coating of target antibody to an ELISA-plate (Nunc Maxisorp 96 well, 281 
flat transparent) followed by a blocking step and incubation with 2x10
5
 reporter cells per well. 282 
For all activation assays, mouse IL-2 secretion was quantified by anti-IL-2 ELISA as 283 
described earlier (49). RhCMV-seropositive rhesus macaque serum was provided by the 284 
German Primate Center Göttingen from pre-existing samples.  285 
 286 
Statistical analysis. Statistical analysis was performed using a two-way analysis of variance 287 
(ANOVA) together with Tukey’s range. Analyses were performed using the Prism 6 software 288 
(GraphPad).  289 
 290 
Rhesus macaques. Adult Macaca mulatta were used at the Oregon National Primate 291 
Research Center (ONPRC) which is accredited by the Association for Assessment and 292 
Accreditation of Laboratory Animal Care. The experiments were conducted in compliance 293 
with the Animal Welfare Act in accordance with the “Guide for the Care and Use of 294 
Laboratory Animals,” Institute of Laboratory Animals Resources, National Research Council 295 
and approved by the Institutional Animal Care and Use Committees (IACUC) that adhere to 296 
national guidelines established in the Animal Welfare Act (7 U.S.C. Sections 2131–2159) and 297 
the Guide for the Care and Use of Laboratory Animals (8th Edition) as mandated by the U.S. 298 
Public Health Service Policy. 299 







Three purpose-bred, pedigreed, male RM were used. At assignment, these RM were positive 300 
for RhCMV but free of Macacine herpesvirus 1, D-type simian retrovirus, simian T-301 
lymphotrophic virus type 1, simian immunodeficiency virus, and TB.  The RM were sedated 302 
with ketamine HCl or Telazol® for subcutaneous administration of 5x10
6
 PFU of either 68-1 303 
RhCMV/gag, RhCMVΔRh01-13.1/gag or 68-1.2 RhCMVgag, respectively, on day 0.  304 
 305 
T cell assays. SIVgag-specific CD4+ and CD8+ T cell responses were measured bi-weekly in 306 
PBMC by intracellular cytokine staining (ICS) (44, 45, 50, 51). Briefly, PBMC were 307 
incubated with consecutive 15mer peptide mixes (11 amino acid overlap) comprising SIVgag 308 
and the co-stimulatory molecules CD28 and CD49d (BD Biosciences) for 1h, followed by 309 
addition of Brefeldin A (Sigma-Aldrich) for an additional 8hrs. Co-stimulation without 310 
peptides served as background control. Alternatively, the MHC-E-restricted SIVgag supertope 311 
peptides (Gag69276-284 RMYNPTNIL and Gag120482-490 EKQRESREK) or MHC-II-restricted 312 
supertope peptides (Gag53211-222 AADWDLQHPQP and Gag73290-301 PKEPFQSYVDRF) 313 
were used in this assay. 314 
Stimulated cells were fixed, permeabilized and stained (44, 45, 50, 51) using combinations of 315 
the following fluorochrome-conjugated mAbs: SP34-2 (CD3; Pacific Blue, Alexa700), L200 316 
(CD4; AmCyan, BV510), SK-1 (CD8; PerCP-Cy5.5), MAB11 (TNFα; FITC, PE), B27 317 
(IFNγ; APC), FN50 (CD69; PE, PE-TexasRed), B56 (Ki-67; FITC), and in polycytokine 318 
analyses, JES6-5H4 (IL2; PE, PE Cy-7). Data was collected on an LSR-II (BD Biosciences). 319 
Analysis was performed using FlowJo software (Tree Star).  Lymphocytes were gated for 320 
CD3+ and progressive gating on CD4+ and CD8+ T cell subsets. Antigen-responding cells in 321 
both CD4+ and CD8+ T cell populations were determined by their intracellular expression of 322 
CD69 and one or more cytokines. After subtracting background, the raw response frequencies 323 
were memory corrected (44, 45, 50, 51) using combinations of the following mAbs to define 324 
the memory vs. naïve subsets: SP34-2 (CD3; Alexa700, PerCP-Cy5.5), L200 (CD4; 325 







AmCyan), SK-1 (CD8; APC, PerCP-cy-5.5), MAB11 (TNFα; FITC), B27 (IFNγ; APC), 326 
FN50 (CD69; PE), CD28.2 (CD28; PE-TexasRed), DX2 (CD95; PE), 15053 (CCR7; Pacific 327 
Blue), and B56 (Ki-67; FITC).  328 
  329 









RhCMV glycoprotein binding to IgG 332 
To determine whether RhCMV encodes viral proteins binding to IgG, purified rhesus IgG 333 
from RhCMV-seronegative RM was incubated with detergent lysates of [35S]methionine-334 
labeled, RhCMV-infected telomerized rhesus fibroblasts (TRF).  For control, we used Fab-335 
fragments generated from rhesus IgG. In addition to the fibroblast-adapted laboratory strain 336 
68-1 which carries a number of gene deletions (36), we also used the primary RhCMV isolate 337 
UCD59 (42) and the recently characterized RhCMV isolates 19269 and 24514 as well as the 338 
cynomolgus CMV (CyCMV) isolate 31908 (43). Bound proteins were eluted from the 339 
protein A/G agarose beads and, where indicated, digested with Endoglycosidase H (EndoH) 340 
to monitor glycan processing during intracellular transport, followed by separation using 341 
SDS-PAGE. As shown in Fig. 1, RhCMV and CyCMV -infected, but not uninfected cell 342 
lysates, contained a single protein species of ~60kDa bound to IgG. This protein was 343 
observed in 68-1-infected cell lysates as well as in lysates from cells infected with primary 344 
NHP CMV isolates. Upon EndoH treatment the molecular weight of the protein was reduced 345 
to ~30kDa suggesting that the protein is highly glycosylated. Both EndoH-sensitive and 346 
EndoH-resistant bands were observed consistent with newly synthesized, EndoH-sensitive 347 
protein sub-populations in the endoplasmic reticulum (ER) that eventually egress to the cell 348 
surface.  349 
 350 
Rh05 encodes a viral FcγR 351 
HCMV encodes four vFcγRs: RL11 (gp34), RL12, RL13 and UL119/118 (gp68). RL11, RL12 352 
and RL13 belong to the RL11 gene family, encoding for a highly polymorphic glycoprotein 353 
family which is also found in RhCMV (36). HCMV gp68 is conserved in RhCMV, including 354 
the spliced gene structure, with the putative homologue encoded by Rh152/151 (35). 355 







However, the gp68 homologue is truncated in RhCMV 68-1 (36) rendering it possibly non-356 
functional. Moreover, the molecular weight of the putative viral Fc receptor was considerably 357 
less than predicted for the gp68 homologue of RhCMV. Therefore, we hypothesized that the 358 
viral IgG-binding protein was likely a member of the RL11 family. In RhCMV, the RL11 359 
family is encoded in the 5’end upstream of the open reading frame (ORF) Rh29 (Fig. 2A). To 360 
determine whether the putative vFcγR is encoded in this gene region we generated two 361 
deletion mutants lacking Rh01-Rh13.1 and Rh14-Rh29 in RhCMV 68-1 by BAC 362 
recombineering (Fig. 2A). Replacement of the desired genomic regions by a FRT-flanked 363 
KanR cassette was confirmed by restriction digest. Upon electroporation of the BACs, virus 364 
was easily recovered, consistent with genes encoded in this genomic region being non-365 
essential for growth in vitro as reported for RhCMV (52) and HCMV (53). To determine 366 
whether ΔRh01-13.1 and ΔRh14-29 contained or lacked the putative IgG binding protein we 367 
metabolically labeled infected RF as above and incubated detergent cell lysates with complete 368 
IgG, Fab-fragments, or Fc-fragments bound to Protein A/G agarose beads or control beads. 369 
Upon electrophoretic separation we observed that lysates of ΔRh14-29-infected cells 370 
contained the ~60kDa (or 30kDa upon deglycosylation) protein that was immunoprecipitated 371 
with both IgG and Fc, but not with F(ab)2 or beads alone (Fig. 2B). In contrast, the 60kDa 372 
protein was not observed in ΔRh01-13.1-infected cell lysates (Fig. 2C) consistent with the 373 
putative vFcγR being encoded in the 5’-terminal region of the genome.  374 
To determine which gene(s) in the Rh01-Rh13.1 region encoded the putative vFcγR we 375 
deleted individual genes in this region from the 68-1 BAC (Fig. 3A). Upon reconstitution of 376 
the single deletion constructs we evaluated IgG binding upon infection of RF. As shown in 377 
Fig. 3B, IgG was able to immunoprecipitate the putative vFcγR from all deletions mutants 378 
except ΔRh05. To ensure that lack of binding was not due to lack of infection and or gene 379 
expression, we also confirmed that ΔRh05 was not essential for infection and growth in vitro 380 







(Fig. 3C). These results suggest that the Rh01-Rh13.1 gene region contains a single vFcγR 381 
encoded by Rh05.   382 
The gene Rh05 encodes for an RL11 family protein of 273 amino-acids (AA) with a predicted 383 
molecular weight of 30.19 kDa. The Rh05 protein displays a type I transmembrane topology 384 
with a predicted cleavable amino-terminal signal peptide (AA1-21), a predicted 385 
transmembrane domain (AA181-207) and a 65AA long cytoplasmic domain (Fig. 4).  386 
Homologous proteins are found in old-world NHP CMVs (Fig. 4). In contrast, none of the 387 
RL11-family proteins of human, great ape, or new world NHP CMV seem be direct homologs 388 
of Rh05. The ectodomain is predicted to belong to the immunoglobulin superfamily and 389 
contains nine putative N-linked glycosylation sites, several of which being highly conserved, 390 
consistent with the protein being highly glycosylated. Also conserved is the C-terminal AA 391 
sequence PATLWL[T/S][K/R] which might represent a subcellular sorting signal. The 392 
predicted characteristics of this protein are thus consistent with the observed MW and 393 
glycosylation pattern of the Fcγ-binding viral protein.  394 
 395 
Recombinant Rh05 is an IgG-Fc binding cell surface protein which antagonizes human 396 
FcγRIIIA/CD16 activation  397 
To examine whether Rh05 has the capacity to counteract host Fcγ-receptor activation, as 398 
reported for the IgG-Fc binding HCMV proteins RL11/gp34 and UL119-118/gp68 (16), we 399 
introduced recombinant Rh05 into an established human Fcγ-receptor activation assay (49). 400 
As a target surface antigen we chose rhesus-CD4 (RhCD4) that can be detected with a 401 
recombinant rhesusized IgG1 monoclonal antibody (αRhCD4 mAb). To this end, we co-402 
transfected Hela cells with RhCD4 (pCDNA3.1 vector) and a polycistronic pIRES_eGFP 403 
vector encoding either recombinant HCMV gp68, RhCMV Rh05 or CD99 control protein 404 
together with GFP as an expression marker which allowed us to monitor transfection 405 
efficiency  (Fig. 5A). As a first step, we wanted to determine whether Rh05 alone would be 406 







sufficient to bind to the Fc portion of IgG on the cell surface. By staining the vFcγR and 407 
RhCD4 co-transfected Hela cells with a TexasRed-conjugated human IgG-Fc fragment and 408 
gating on the above mentioned GFP-positive population we observed that Rh05 is a potent 409 
IgG-Fc binding protein compared to HCMV gp68 which served as a positive control (Fig. 5B, 410 
left). A human IgG-Fc fragment was used as previous observations already showed high 411 
cross-reactivity between human and nonhuman primate IgG-Fc (28, 29). In these experiments, 412 
HCMV gp68 was expressed as a fusion protein to the transmembrane domain and cytosolic 413 
tail of human CD4 since this fusion protein reaches higher densities on the plasma membrane 414 
upon transient expression than wildtype gp68 (Kolb and Hengel, unpublished observation). 415 
Surface expression of co-transfected RhCD4 and binding of αRhCD4 to its antigen in co-416 
transfected Hela cells was demonstrated by detection of RhCD4 using PE-conjugated 417 
αRhCD4 (Fig. 5B, right). Gating on GFP-positive cells allowed us to conclude that cells 418 
expressing Rh05, gp68 or CD99 uniformly expressed the target antigen RhCD4 and that 419 
surface levels of RhCD4 are not affected by co-transfected genes of interest (Fig. 5B, right).  420 
 To address the antagonistic potential of Rh05, the co-transfected cells were then co-cultured 421 
with a reporter cell line expressing the human FcγRIIIA/CD16 ectodomain fused to the CD3-422 
ζ-chain signaling module (BW5147-human-CD16-ζ) after adding graded amounts of 423 
αRhCD4. Reporter cell activation was quantified by measuring IL-2 production using a 424 
sandwich ELISA as described previously (49). As shown in Fig. 5C, compared to the 425 
expression of a non-Fcγ-binding control molecule (CD99) we observed a significant and 426 
antibody dose-dependent reduction of CD16-reporter cell activation by target cells expressing 427 
Rh05 that exceeded the inhibition mediated by gp68. Control BW cells lacking the CD16 428 
FcγR (parental cells) were not activated. Taken together, these data demonstrate that Rh05 429 
represents an IgG-Fc binding glycoprotein with the potential to antagonize the activation of 430 
host FcγRs. 431 
 432 







Rh05 protects RhCMV-infected cells from Fcγ-receptor activation by opsonizing IgG  433 
The potent inhibition of human CD16 activation by Rh05 supported our hypothesis that this 434 
vFcγR might protect infected cells from Macaca mulatta FcγR-dependent effector 435 
mechanisms. To this end we generated BW reporter cells encoding chimeric rhesus (Rh) 436 
CD16, RhCD32A, RhCD32B or RhCD64 consisting of the extracellular FcγR domain fused 437 
to the transmembrane and intracellular domains of the mouse CD3ζ chain. FcγR-activation 438 
can thus be monitored by production of interleukin-2 (IL-2). Surface expression and intact 439 
ligand binding of these chimeric Rh-FcγRs was demonstrated by flow cytometry using a 440 
TexasRed conjugated human IgG-Fc fragment (Fig. 6A, left). Next, the ability of these 441 
reporter cell lines to generate IL-2 upon FcγR activation was verified by receptor cross-442 
linking by immobilized IgG of human and rhesus origin. All reporter cell lines responded to 443 
human IgG1 mAb Rituximab® or  αRhCD4 (Fig. 6A, middle). Of note, BW-RhCD16ζ 444 
yielded lower signals compared to the other cell lines including BW cells expressing human-445 
CD16ζ. This could be due to the fact that IgG from individual sources can have highly 446 
varying affinities to certain isoforms of Rh-FcγRs (29). Interestingly, the dose-response of 447 
BW-Rh64ζ cells in this context did not reach an activation plateau that was maintained at high 448 
antibody concentrations, but displayed a maximum response at lower antibody concentrations 449 
(Fig. 6A, right). In contrast, all other reporter cell lines (including reporter cells expressing 450 
hCD64) showed the typical sigmoidal dose-response with plateau activation to the 451 
immobilized antibodies above a given antibody concentration (data not shown). While we 452 
cannot fully explain this observation, it is possible that RhCD64 reaches suboptimal activation 453 
with high amounts of immobilized IgG due to its intrinsic molecular characteristics as a high-454 
affinity FcγR which bind to but are not activated by monomeric IgG (29, 30).  455 
With these reporter cell lines in hand, we then set out to assess the effect of Rh05 on Rh-FcγR 456 
activation. To this end, TRF infected with RhCMV 68-1 or RhCMVΔRh05 were incubated 457 
with polyclonal immune serum from RhCMV-positive or -negative animals and then co-458 







cultured with the respective reporter cell lines. As expected, surface antigen levels were 459 
similar between cells infected with either RhCMV 68-1 or RhCMVΔRh05, as demonstrated 460 
by flow cytometry detecting the bound anti-RhCMV serum via a FITC-conjugated polyclonal 461 
anti-human antibody (Fig. 6B, left). In contrast, IgG-Fc binding was only observed for TRF 462 
infected with RhCMV 68-1, but not RhCMVΔRh05 consistent with a complete loss of Fc-463 
binding activity upon deletion of Rh05 (Fig. 6B, right). Applying the FcγR reporter assay, 464 
serum from the RhCMV-seropositive animal elicited the typical dose-dependent response in 465 
the reporter cell lines, except for RhCD64 which again showed maximal stimulation at lower 466 
serum concentrations (Fig. 6C). Serum from the RhCMV-negative animal did not induce IL-2 467 
in any of the reporter cells (Fig. 6C). Importantly, compared to cells infected with RhCMV 468 
68-1, cells infected with RhCMVΔRh05 induced significantly higher reporter cell activation 469 
for all examined activating Rh-FcγRs at dilutions of RhCMV-immune serum that elicited 470 
maximal stimulation (Fig. 6C). Although there was a similar tendency for the inhibitory 471 
RhCD32B receptor, the differences between the RhCMVΔRh05 and 68-1 RhCMV did not 472 
reach statistical significance. Based on these results we conclude that Rh05 limits the ability 473 
of IgG antibodies bound to infected cells to activate host FcγRs thus counteracting 474 
opsonization and subsequent FcγR mediated immune responses. 475 
 476 
Re-infection by RL11-family-deleted RhCMV 477 
A unique aspect of both RhCMV and HCMV is their ability to establish secondary persistent 478 
infections in CMV-immune hosts. We previously demonstrated that viral evasion of CD8+ T 479 
cells by US6-family viral inhibitors of MHC-I antigen presentation is necessary for RhCMV 480 
to re-infect RhCMV-seropositive animals (6). Furthermore, preventing the activation of NK 481 
cells by inhibiting the cell surface expression of ligands for activating NK-cell receptors 482 
proved to be essential for RhCMV infection in both RhCMV seropositive and seronegative 483 
hosts (39). Therefore, we were wondering whether the vFcγR Rh05 would be required for 484 







RhCMV to overcome pre-existing humoral immunity. T cell responses to heterologous 485 
antigens expressed by RhCMV can be used as a surrogate measure for the ability of RhCMV 486 
to re-infect seropositive animals (6). Thus, we took advantage of the SIVgag gene inserted 487 
during the construction of ΔRh01-13.1 (see material and methods). 5x10
6
 PFU of ΔRh01-13.1 488 
was inoculated sub-cutaneously and the T cell response to SIVgag was measured biweekly in 489 
PBMC by intracellular cytokine staining (ICS) using overlapping peptides spanning the 490 
SIVgag sequence. As shown in Fig. 7A, ΔRh01-13.1 elicited robust SIVgag-specific 491 
responses for both CD4+ and CD8+ T-cells that were comparable to inoculation of 68-1 492 
RhCMV/gag into a different animal. While these results were only obtained in one animal, 493 
they clearly demonstrate that the gene region containing Rh05 is not essential for infection 494 
and re-infection.  495 
We recently reported that recombinant viruses based on strain 68-1, but not the pentamer-496 
intact derivative RhCMV 68-1.2, elicit CD8+ T cells that recognize peptides exclusively in 497 
the context of MHC class II or the non-polymorphic MHC-E molecule instead of polymorphic 498 
MHC-Ia (44, 51). Moreover, some MHC-II and MHC-E-restricted SIVgag peptide epitopes, 499 
termed “supertopes”, are consistently recognized in every animal tested so far (>100 animals). 500 
To determine whether genes encoded in the Rh01-13 region affected this T cell programming 501 
we measured the CD8+ T cell responses to two MHC-II and two MHC-E supertopes. Similar 502 
to total SIVgag responses, we observed that both 68-1 RhCMV/gag and ΔRh01-13.1 elicited 503 
supertope-specific CD8+ T cells in contrast to 68-1.2 RhCMV/gag that failed to elicit CD8+ 504 
T cells to these supertopes (Fig. 7B). These results suggest that deletion of Rh05, or any of 505 
the other genes encoded in the 5-terminal region of RhCMV, does not impact the ability of 506 
RhCMV 68-1 to elicit CD8+ T cells to unconventional epitopes.   507 








Our results demonstrate that RhCMV Rh05 encodes an IgG-Fc binding glycoprotein that 509 
immobilizes antibodies at the cell surface. Using a cell-based assay to measure rhesus IgG 510 
mediated activation of rhesus FcγRs, we further show that Rh05 expressed on the surface of 511 
infected cells is a potent antagonist of host FcγR activation by anti-CMV antibodies. Based on 512 
these results we conclude that Rh05 is a vFcγR that counteracts the ability of CMV-specific 513 
antibodies to trigger activating host FcγRs thus supporting viral immune evasion. 514 
Rh05 is the first vFcγR identified in RhCMV. Although Rh05 does not show direct homology 515 
to any of the previously identified vFcγRs in HCMV, the protein belongs to the same RL11 516 
gene family as three of the four HCMV vFcγRs:  RL11 (gp34), RL12, and RL13 (16, 54). 517 
Similar to gp34 which is able to block all of the activating human FγRs - FcγRI (CD64), 518 
FcγRIIa (CD32a) and FcγRIIIa (CD16) – we observed that Rh05 reduced the activation of 519 
homologous rhesus FcγRs. The diverse RL11 glycoprotein family is characterized by the ~ 80 520 
AA RL11 domain containing a conserved tryptophan and two cysteine residues (55, 56). In 521 
addition to encoding vFcγRs, members of this gene family have been involved in various 522 
immunomodulatory functions (57-61) as well as viral modulation of angiogenesis, cell 523 
differentiation and reactivation (62, 63). Mutations in the RL13 glycoprotein are rapidly 524 
selected in both HCMV and NHP CMVs in tissue culture due to increased growth of RL13-525 
defective variants (43, 64). Due to two frame-shift mutations, RhCMV strain 68-1 used in this 526 
study is also predicted to lack a functional RL13 homologue (Rh13.1) suggesting that the 527 
negative impact of this protein on viral growth in vitro is conserved (36). However, it is 528 
presently not known whether intact Rh13.1 also shares the ability to bind Fc with HCMV 529 
RL13. Similarly, it is not known whether the RhCMV homologue of HCMV UL118/119 530 
(gp68) is a functional vFcγR. However, given the significant homology including the spliced 531 
gene structure, this is highly likely. Interestingly, the Rh151/152 gene encoding the gp68 532 
homolog is truncated and possibly non-functional in RhCMV 68-1 (36). Conceivably, 533 







wildtype RhCMV could thus encode additional vFcγRs compared to RhCMV 68-1. However, 534 
we observed only a single viral protein band corresponding in size to Rh05 535 
immunoprecipitating with IgG in lysates from cells infected with low passage isolates of 536 
RhCMV and CyCMV (Fig.1). Thus, it is also conceivable that Rh05 is the only vFcγR in 537 
NHP CMVs. By studying the homologs of RL13 and gp68 in isolation we will be able to 538 
examine this possibility.   539 
To determine the impact of vFcγR expression on host Fc receptor activation we introduced 540 
Rh-FcγRs into our previously developed FcγR activation assay (49). We showed that this 541 
assay delivered reproducible, quantifiable measurements of FcγR activation via immune IgG 542 
when applied to infected cells opsonized with polyclonal serum in the context of herpes 543 
simplex virus, HCMV and influenza virus (16, 31, 65). In a mouse influenza virus model, 544 
comparative FcγR assay results closely correlated with the protective capacity of antiviral 545 
IgGs in vivo (31). By generating Rh-FcγRs fused to mouse CD3ζ we were able to measure the 546 
antibody dose-dependent effect of FcγR-activation by antibody binding to RhCMV-infected 547 
cells. In doing so, we uncovered an unexpected IgG concentration-dependent optimum of 548 
rhesus CD64/FcγRI activation (Fig. 6A,C). In contrast, human FcγRI activation plateaued at 549 
high concentrations in this assay system (16). The finding that higher antibody concentrations 550 
result in lower FcγR activation could potentially reflect a unique feature, possibly a specific 551 
isoform, of the high affinity rhesus FcγRI.  552 
It is thus possible that the rhesus FcγRI receptors are functionally different from human FcγRI 553 
receptors. However, the homology between RM and human FcγRs is approximately 95%, 554 
87% and 91% for FcγRI, RII and RIII, respectively (29). Some polymorphisms are observed 555 
in RM, particularly for FcγRIIA, some of which resulting in impaired antibody binding (29). 556 
However, the allotypic variants in this study (FcγRI-3, FcγRIIA-1, FcγRIIB-1, FcγRIIIA-1) 557 
were previously shown to be fully functional but differed with respect to IgG subclass 558 







specificity (29). Importantly, Rh05 was able to interfere with the activation of each activating 559 
RM FcγR by polyclonal RM serum, suggesting that Rh05 broadly binds IgG subclasses.  560 
Unlike RhCMV lacking the gene region Rh182-189, encoding proteins that prevent MHC-I 561 
antigen presentation, or RhCMV lacking NKG2D-ligand-retaining Rh159, deletion of the 562 
gene region encompassing Rh05 did not affect the ability of RhCMV to overcome pre-563 
existing immunity and establish a secondary infection. If Rh05 is indeed the only vFcγR 564 
encoded by RhCMV, this result would indicate that evasion of antibodies is not essential for 565 
super-infection. Alternatively, Rh05 is the not the only vFcγRs and other, yet to be identified, 566 
vFcγRs support reinfection. In either case however, these results do not rule out that Rh05 567 
supports viral replication, dissemination and/or shedding. For instance, although strain 68-1 568 
RhCMV is clearly able to establish secondary persistent infections in RhCMV-seropositive 569 
RM, this highly passaged strain is clearly attenuated compared to low-passage isolates such as 570 
UCD59 resulting in decreased plasma viral titers and decreased shedding during acute 571 
infection (41). A more detailed study requiring a larger cohort size will thus be required to 572 
quantify the impact of Rh05 on RhCMV infection.  573 
It will also be interesting to study the impact of Rh05 deletion, alone or together with 574 
additional putative vFcγRs discussed above, in settings of passive immunization with anti-575 
RhCMV antibodies. The importance of IgG-Fc interaction with host FcγRs for protection by 576 
passive immunization against viruses has been illustrated in animal models of influenza and 577 
HIV (32, 33, 66). In the case of HIV, it has further been shown that viral Ab escape mutants 578 
arise in an Fc-dependent manner (33). However, large DNA viruses like CMV likely contain 579 
multiple epitopes targeted by antibodies, which renders it difficult for the virus to escape 580 
immune pressure by mutation. Conceivably, vFcγRs evolved to enable antibody escape by 581 
CMVs regardless of the epitope targeted thus limiting the ability of both neutralizing and non-582 
neutralizing antibodies to prevent viral spread in vivo. This immune evasion mechanism might 583 
therefore limit the efficacy of passively administered immunoglobulins to prevent congenital 584 







infection by CMV (9). The identification of a vFcγR in a highly relevant animal model of 585 
HCMV will help to develop a better understanding of the role of vFcγRs in counteracting 586 
immune responses elicited by vaccines and immunotherapies which might be improved by 587 
reagents that block vFcγR function.  588 
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Figure legends 604 
Figure 1: RhCMV encodes an IgG binding protein 605 
To detect IgG binding proteins, lysates from metabolically labelled TRFs were incubated with 606 
serum from RhCMV-naïve RM and total IgG was immunoprecipitated using Protein A/G 607 
Agarose. Endoglycosidase H (EndoH) was added where indicated. A) Uninfected cell lysate. 608 
B) TRFs were infected with RhCMV 68-1 (MOI = 3) for 72 hrs prior to metabolic labelling. 609 
Infected cell lysates were either untreated, incubated with purified Fab fragments or whole 610 
serum. Immunoprecipitates were separated by SDS-PAGE and protein bands visualized by 611 
autoradiography. C) TRFs were infected with RhCMV 68-1 or the low passage isolate 612 
UCD59 (MOI = 3) for 72 hrs prior to metabolic labelling and immunoprecipitation. D) TRFs 613 
were infected with RhCMV 68-1 or the indicated RhCMV and CyCMV low passage isolates 614 
(MOI = 3) for 72 hrs prior to metabolic labeling. IgG immunoprecipitations after incubation 615 
with CMV naïve RM serum were performed using Protein A/G Agarose. Arrows indicate a 616 
single EndoH sensitive glycoprotein species. *indicates a non-specific protein. 617 
 618 
Figure 2: The IgG-binding protein is encoded in the 5’ end of the RhCMV genome 619 
A) Schematic overview of the 5’-end genomic region of RhCMV encompassing the RL11 620 
gene family. All RL11 gene family members are highlighted in dark grey. Two deletion 621 
mutants, ΔRh01-Rh13.1 and ΔRh14-ΔRh29, that together span the entire RL11 gene family, 622 
were constructed. The exact region that was deleted in each mutant is indicated by the boxed 623 
area. B) and C) TRFs were infected with the indicated deletion mutants or with RhCMV 68-1 624 
WT control at an MOI of 3 for 72 hrs prior to metabolic labelling. Lysates were either mock 625 
incubated or incubated with purified Fab fragments, purified Fc fragments or whole serum. 626 
IgG was immunoprecipitated and treated with EndoH where indicated. Arrows indicate the 627 
glycosylated and de-glycosylated forms of the RhCMV encoded protein that co-precipitates 628 
with RM IgG or RM IgG Fc fragments from RhCMV 68-1 and from RhCMVΔRh14-29, but 629 







not from RhCMVΔRh01-13.1. *indicates a non-specific protein. All other unmarked proteins 630 
species are also non-specific.  631 
 632 
Figure 3: Rh05 encodes a viral Fc binding protein 633 
A) Schematic overview of the RhCMV deletion mutants constructed by BAC recombineering. 634 
The entire viral ORF was deleted in each case as indicated by the boxes. B) 635 
Immunoprecipitations of IgG of RhCMV-naïve serum incubated with lysates from TRFs 636 
infected with the single deletion mutants (MOI-3) for 72 hrs. Half of every sample was 637 
EndoH treated as indicated. Arrows indicate the glycosylated and non-glycosylated form of 638 
the IgG binding protein. *indicates a non-specific protein. C) Multistep growth curve of 639 
RhCMV 68-1 and RhCMVΔRh05 on primary rhesus fibroblasts. The cells were infected with 640 
an MOI of 0.01, samples were harvested every third day and viral titers were determined by 641 
TCID50. 642 
 643 
Figure 4: RhCMV Rh05 is conserved in old world monkey CMV species 644 
An alignment of the predicted amino acid sequence of Rh05 with putative homologues of 645 
Cynomolgus CMV 31908 (CyCMV), Simian CMV Colburn (SCMV), Baboon CMV 646 
OCOM4-37 (BaCMV) and Drill monkey CMV OCOM6-2 (DrCMV) was generated using the 647 
CLUSTAL O (1.2.4) multiple sequence alignment tool. Highlighted are the predicted signal 648 
sequence (green, predicted using the SignalP 4.1 Server), transmembrane region (blue, 649 
predicted using the Phobius Server) and potential glycosylation sites (red, using the NetNGlyc 650 
1.0 Server). Additionally, amino acids that that have been defined as conserved across the 651 
RL11 family of proteins were circled in black.  652 
 653 
Figure 5: Rh05 binds IgG-Fc and antagonizes antibody-dependent FcγR activation 654 







Hela cells were co-transfected with the target antigen rhesus-CD4 (RhCD4; pcDNA3.1) and 655 
either of the indicated genes of interest (CD99, HCMV UL119-118 and RhCMV Rh05; 656 
p_IRES-eGFP). A) GFP positive cells, gated on live cells using DAPI, were plotted against 657 
side scatter. The GFP-positive population, indicated by a gate, demonstrates similar 658 
transfection rates for each of the genes of interest. B) Left Panel: GFP-positive cells from A 659 
were analyzed for Fcγ-binding by flow cytometry using Texas Red conjugated human-Fcγ 660 
fragment. RhCMV Rh05 and HCMV gp68 bound to IgG-Fc whereas CD99 was negative. 661 
Right Panel: Surface expression levels of RhCD4 are not affected by co-expressed genes of 662 
interest. RhCD4 was detected in the GFP-positive population from A using a PE-conjugated 663 
rhesusized anti-RhCD4 mAb. C) Rh05 antagonizes antibody-dependent Fcγ-receptor 664 
activation. HeLa cells co-transfected with RhCD4 and the indicated genes of interest were 665 
incubated with rhesusized anti-RhCD4 mAb and subsequently co-cultured with BW reporter 666 
cells expressing the chimeric human receptor CD16ζ (left) or parental BW5147 cells (right). 667 
IL-2 levels corresponding to reporter activation were quantified using ELISA. Error bars = 668 
SD. Two-way ANOVA (Tukey); gp68 vs. CD99 (black), Rh05 vs. CD99 (orange). 669 
 670 
Figure 6: Rh05 antagonizes FcγR-stimulation by infected cells 671 
A) Left: Surface expression of chimeric rhesus Fcγ-receptors RhCD16ζ, RhCD32Aζ, 672 
RhCD32Bζ and RhCD64ζ on stably transduced BW cells was detected using Texas Red-673 
conjugated human Fcγ fragment. Parental BW cells were used as a control. Middle: Chimeric 674 
rhesus FcγRs are activated upon IgG-Fc binding. Indicated BW reporter cells were assessed 675 
for activation by immobilized antibodies (Rtx = Rituximab; αRhCD4 = recombinant 676 
rhesusized anti-rhesus-CD4 mAb). All values are means of technical duplicates and represent 677 
plateau activation determined by incubation on titrated amounts of antibody (not shown). 678 
Right:  dose-response upon RhCD64 reporter cell activation by titrated amounts of Rtx. B) 679 
TRF cells were infected with RhCMV 68-1 or RhCMVΔRh05 using centrifugal enhancement 680 







at an MOI=2 for 72hr. Left: Infected cells were incubated with serum from a RhCMV sero-681 
positive monkey and overall surface antigen expression was detected via a FITC-conjugated 682 
rabbit anti-human-IgG polyclonal antibody. Right: Infected cells were probed with a 683 
TexasRed-conjugated human IgG-Fc fragment. C) Rh05 antagonizes rhesus-FcR activation 684 
by antibody bound to infected cells. Infected cells were incubated with serum dilutions of 685 
RhCMV-positive or RhCMV-negative monkeys and subsequently co-cultured with the 686 
indicated BW reporter cells. IL-2 levels corresponding to reporter activation were quantified 687 
using ELISA. Error bars = SEM; CMV-positive sera = averages of 2 independent 688 
experiments; CMV-negative sera = averages of 1 experiment. Two-way ANOVA (Tukey). 689 
Asterisks show statistical comparison of reporter responses to infected cells opsonized by 690 
RhCMV-positive serum. 691 
 692 
Figure 7: Rh05 is not required for superinfection.  693 
At day 0, a RhCMV-positive RM was infected subcutaneously with 5x10
6
 PFU of the 694 
indicated recombinant virus and the SIVgag-specific T cell responses in PBMC were 695 
monitored by ICS for CD69, TNFα and IFNγ either using overlapping SIVgag 15mer peptide 696 
mixes to measure total responses (A) or the indicated MHC-E and MHC-II supertopes to 697 





 T cells.  699 
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